EUVIMEDEUVIMED entdecken
Crossref

Optimizing Linezolid Dosing in Lung Transplant Recipients: Population Pharmacokinetics, Target Attainment, and Thrombocytopenia Risk Assessment

Dan Zhang iD, Wenwen Du, Pengmei Li, Wenqian Chen, Xiaoxing Wang

The Journal of Clinical Pharmacology · 2026

DOI: 10.1002/jcph.70153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Dan Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, China-Japan Friendship Hospital, Beijing, China. Hauptthemen laut MEDLINE: Lung Transplantation, Linezolid, Thrombocytopenia, Anti-Bacterial Agents. Die Arbeit nennt 25 Literaturangaben. Gefördert von: National Key Laboratory of Respiratory Comorbidity Independent Project, National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The pharmacokinetic (PK) profiles of linezolid in lung transplant recipients (LTRs) differ from those in other patients. This study aimed to develop a population pharmacokinetic (PopPK) model to evaluate dosage regimens based on various biological covariates and assess the risk of thrombocytopenia. The nonlinear mixed‐effects modeling method was employed to establish the PopPK model. Monte Carlo simulations assessed the probability of target attainment (PTA) under different covariates and minimum inhibitory concentration (MIC) ranges. The study included 43 LTRs with 142 linezolid concentration–time data points. The final model identified estimated glomerular filtration rate and tacrolimus trough level as key covariates for apparent clearance. The 300 mg bid regimen maintained peak and trough concentrations within the 2–8 mg/L range, while the 600 mg qd dosing group achieved a PTA greater than 80% across an MIC range of 0.25–1 mg/L. Linezolid C min impacted platelet levels, with baseline levels influencing the severity of reduction. This PopPK model offers valuable insights for optimizing linezolid dosing, considering immunosuppressant therapy and thrombocytopenia risk, and serves as a reference for dose selection in post‐surgical LTRs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung TransplantationLinezolidThrombocytopeniaAnti-Bacterial AgentsModels, BiologicalHumansFemaleMaleMonte Carlo MethodMiddle AgedRisk AssessmentMicrobial Sensitivity TestsAdultImmunosuppressive AgentsAgedDose-Response Relationship, DrugTransplant Recipients

Stichwörter der Autor:innen

linezolidlung transplantpharmacokinetics/pharmacodynamicsthrombocytopenia

Substanzen

LinezolidAnti-Bacterial AgentsImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Pharmacy, China-Japan Friendship Hospital, Beijing, China.

ORCID-Profile: Dan Zhang

Förderung

  • National Key Laboratory of Respiratory Comorbidity Independent Project
  • National High Level Hospital Clinical Research Funding

Zitieren

APA

Zhang, D., Du, W., Li, P., Chen, W., & Wang, X. (2026). Optimizing Linezolid Dosing in Lung Transplant Recipients: Population Pharmacokinetics, Target Attainment, and Thrombocytopenia Risk Assessment. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70153

Vancouver

Zhang D, Du W, Li P, Chen W, Wang X. Optimizing Linezolid Dosing in Lung Transplant Recipients: Population Pharmacokinetics, Target Attainment, and Thrombocytopenia Risk Assessment. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70153

BibTeX
@article{Zhang2026,
  author = {Zhang, Dan and Du, Wenwen and Li, Pengmei and Chen, Wenqian and Wang, Xiaoxing},
  title = {Optimizing Linezolid Dosing in Lung Transplant Recipients: Population Pharmacokinetics, Target Attainment, and Thrombocytopenia Risk Assessment},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/jcph.70153}
}
Kostenlos starten →